Pathological complete response and long-term survival by pembrolizumab based immunochemotherapy in epidermal growth factor receptor mutated non-small cell lung cancer post-tyrosine kinase inhibitor failure: a case report and tumor microenvironment analysis.

Lung adenocarcinoma harboring epidermal growth factor receptor ( A 74-year-old female patient with stage IVa  This case report highlights the potential of pembrolizumab-based ICT to induce a pCR and achieve long-term survival in